Clinical Trial Update: Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Anastrozole with or without Gefitinib in postmenopausal women with metastatic or locally recurrent breast cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Iressa (gefitinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED